Mast Therapeutics Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
January 7, 2016 12:01 PM UTCMaxim Group analyst Jason Kolbert reiterated a Buy rating and $5 price target on Mast Therapeutics (NYSE: MSTX) noting pivotal data in sickle cell ahead and pipeline progress.
Kolbert highlighted:
Management provided a detailed update, highlighting key clinical and regulatory milestones in 2016 including the status of the pivotal phase III "EPIC" study (N=388) of vepoloxamer in sickle cell disease (SCD). We remain... More